Zhitong Financial App News, Guangji Pharmaceutical (000952.SZ) released a report for the first three quarters of 2023, with operating revenue of 522 million yuan, down 2.57% from the same period last year. The net loss attributed to the shareholders of the listed company was 66.9762 million yuan, from profit to loss compared with the same period last year. The net loss of 70.1963 million yuan after deducting non-recurring profits and losses belonging to the shareholders of the listed company. Basic earnings per share-0.1892 yuan.
广济药业(000952.SZ)发前三季度业绩，净亏损6697.62万元，同比由盈转亏
Guangji Pharmaceutical (000952.SZ) released its results for the first three quarters, with a net loss of 66.97762 million yuan, from profit to loss over the previous year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.